Sofinnova Partners Announces Third Investment From Its Italian Fund
20.4.2020 10:00:00 EEST | Business Wire | Press release
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today an investment in Genespire, a Milan-based gene-therapy company developing best-in-class therapies for patients affected by genetic diseases. This is the third investment for the Sofinnova Telethon Fund, bringing the total financing of Italian startups by Sofinnova Partners to €25 million over the past six months. The Sofinnova Telethon Fund is the largest fund in Italy dedicated to biotechnologies, making early-stage investments in Italian companies targeting cures for rare and genetic diseases.
Genespire was spearheaded by the renowned gene therapy pioneer Professor Luigi Naldini. This investment by the Sofinnova Telethon Fund follows on the heels of its leading-edge investments in Epsilen Bio, which is developing a technology to turn off genes linked to specific pathologies without irreversibly modifying the DNA (a major potential safety advantage), and PinCell, a pre-clinical stage biotech company focused on the development of new therapies for rare dermatological diseases.
“These investments are the result of the excellent collaboration between Sofinnova Partners and The Telethon Foundation,” said Graziano Seghezzi, Managing Partner of Sofinnova Partners. “These exceptional start-up companies validate our conviction in the strength of the Italian market for supporting biotechnological advances.”
The Sofinnova Telethon Fund, managed by Sofinnova Partners, received commitments totaling €108 million, exceeding its target and establishing it as the largest fund to emerge from ITATech, a joint venture between the European Investment Fund (EIF) and Italy’s Cassa Depositi e Prestiti (CdP). “We have gained unprecedented levels of support from Italian investors for our Italian biotech fund,” added Mr. Seghezzi. “We are proud and humbled by the trust we received from some of the country’s leading institutional, corporate and private investors who more than doubled the initial support provided by ITATech.”
Francesca Pasinelli, CEO of The Telethon Foundation, said the biggest winners of this partnership would be the patients who suffer from rare and genetic diseases. “This Fund has always been about them and additionally, is dedicated to elevating Italian science, supported by Italian investors and focused on Italy’s best entrepreneurs and companies,” she said. “We are seeing deep synergies between what we are doing with Sofinnova Partners and our ongoing, fruitful collaboration with the San Raffaele Hospital.”
The Sofinnova Telethon Fund team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the Milan office. The office also houses BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners in collaboration with Silvano Spinelli and Gabriella Camboni, two serial entrepreneurs with close ties to Sofinnova Partners. Ms. Faccio has over 20 years of experience in the domain as the Director of Research and Business Development of The Telethon Foundation and as the Director of the Technology Transfer Office at the San Raffaele Hospital. Ms. Pozzi, who succeeded Ms. Faccio at the San Raffaele Hospital, has 16 years of experience in patent portfolio market-oriented management and development leading to incorporation of new companies with strong IP assets.
The Sofinnova Telethon Fund will continue to invest exclusively in Italy, seeking to identify, create and develop some of the best companies in the field of rare and genetic diseases.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
About Genespire
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Prof. Alessio Cantore, The Telethon Foundation and San Raffaele Hospital. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and backed by Sofinnova Partners.
About Epsilen Bio
Epsilen Bio is a biotechnology company developing transformative therapies for patients affected by underserved medical conditions, through stable and long-lasting epigenetic silencing of genes involved in pathological processes. Based in Milan, Italy, Epsilen Bio was founded in December 2019 by the renowned gene therapy experts Prof. Angelo Lombardo and Prof. Luigi Naldini, The Telethon Foundation and San Raffaele Hospital. Epsilen Bio is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute, and received seed funding from Sofinnova Partners. For more information, please visit: www.epsilenbio.com
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapy for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners. For more information, please visit: www.pincell.it
About The Telethon Foundation (Fondazione Telethon)
The Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a group of stakeholders, who saw scientific research as the only real opportunity to fight genetic diseases and win. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 28 years of activity, Fondazione Telethon has invested more than € 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of research with a view to developing treatments. For more information, please visit: www.telethon.it
About San Raffaele Hospital (Ospedale San Raffaele)
Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part of Gruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patient’s bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctors to grow professionally. For more information, please visit: www.hsr.it
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005174/en/
Contact information
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
Italy
Havas PR Milan
Marco Fusco
Marco.fusco@havaspr.com
+39 (0) 3456538145
Antonio Buozzi
antonio.buozzi@havaspr.com
+39 (0) 3200624418
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneyco.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SymphonyAI Launches CINDE Retail Media Intelligence to Connect Merchandising and Media for Mid-to-Large Grocers2.6.2026 01:05:00 EEST | Press release
Retail media has become the fastest-growing profit line in grocery, yet the billions of dollars CPG advertisers invest in it every year flow through a system where media buyers and merchants never see the same data. Merchants plan assortments, negotiate trade spend, and execute resets with no visibility into which CPG media investments are driving category velocity, while CPG advertisers renew or walk based on incrementality proof that most retailers cannot provide. To solve for this, SymphonyAI, a global leader in Vertical AI, today announced the general availability of CINDE Retail Media Intelligence (RMI), an AI platform that connects merchandising, media, and shopper intelligence into a single closed-loop system, giving retailers and CPG partners shared visibility into how every media dollar moves category turns, trade spend ROI, and gross margin across every reset cycle, joint business planning negotiation, and campaign flight. This press release features multimedia. View the full
SES Launches Multi-Orbit Satellite Connectivity on Mexico’s Viva1.6.2026 21:00:00 EEST | Press release
SES, a leading space solutions company, and Viva, Mexico’s ultra low-cost airline, launched fast and reliable multi-orbit satellite inflight connectivity service on Viva’s Airbus aircraft, strengthening SES’s position as a leading provider of satellite-powered broadband inflight service in the Americas and around the world. “Viva’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’ partnerships with growing airlines like Viva highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is the engine that powers inflight connectivity, a trusted partner that makes airline operations easier,” said Mike DeMarco, SES President of Mobility. A total of 60 A320s and 40 A321s are set to offer the SES solution in the coming years. With the youngest Latin American fleet of Airbus A320s and A3
Motive Powers Latin America’s Next Wave of Mobile Innovation1.6.2026 18:00:00 EEST | Press release
Motive, a global leader in entitlement and connected device & service management, joined operators and industry leaders at M360 LATAM in Mexico City, showcasing live deployments across the region's most consequential use cases: Satellite Direct-to-Device connectivity for unreachable geographies, end-to-end eSIM provisioning and visibility at scale, and SIM-based silent authentication replacing fraud-exposed SMS OTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260531906729/en/ Across landmark deployments with multiple Claro, Vivo, and Entel operations, Motive’s Entitlement Server (Motive ES) has moved from infrastructure component to regional growth engine. These deployments are citing measurable commercial growth, enabling streamlined eSIM provisioning, improved device onboarding experiences, and new revenue opportunities tied to digital services and secure identity. Powered by Motive ES, Entel Chile became the first mobi
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analysis or the ability to develop and execute sophisticated trading strategies.” Clients can link their existing IBKR account thro
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 16:01:00 EEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom